STOCK TITAN

Oscar Health Announces Strong Results for Fourth Quarter and Full Year 2023; Introduces Full Year 2024 Outlook Including Total Company Adjusted EBITDA Profitability

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Oscar Health, Inc. announces its financial results for the fourth quarter and full year ended December 31, 2023. Total Direct and Assumed Policy Premiums for 2023 were $6.6 billion, down 3% YoY. Premiums earned of $5.7 billion increased 47% YoY. Medical Loss Ratio improved 370 bps YoY to 81.6%. InsuranceCo Combined Ratio improved 640 bps YoY to 99.5%. Adjusted EBITDA loss of $45 million improved by $417 million YoY. Net loss of $271 million improved by $339 million YoY. The company anticipates Total Revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, a SG&A Expense Ratio of 20.5% to 21.0%, and Total Company Adjusted EBITDA of $125 million to $175 million for 2024.
Positive
  • Premiums earned increased by 47% YoY
  • Medical Loss Ratio improved by 370 bps YoY to 81.6%
  • InsuranceCo Combined Ratio improved by 640 bps YoY to 99.5%
  • Adjusted EBITDA loss of $45 million improved by $417 million YoY
  • Net loss of $271 million improved by $339 million YoY
  • The company anticipates Total Revenue of $8.3 billion to $8.4 billion for 2024
Negative
  • Total Direct and Assumed Policy Premiums for 2023 decreased by 3% YoY
  • Adjusted EBITDA loss of $45 million

Insights

The reported net loss of $271 million and the Adjusted EBITDA loss of $45 million for Oscar Health, despite being an improvement from the previous year, signal a significant challenge in achieving profitability. The improvements in the Medical Loss Ratio and Administrative Expense Ratio demonstrate effective cost management and pricing strategies, which are crucial for the company's future financial health. Investors should monitor these metrics closely as they are indicative of the company's ability to manage expenses relative to revenue.

However, the 3% decrease in Direct and Assumed Policy Premiums may raise concerns about market share and competitive positioning. As Oscar Health projects a substantial increase in Total Revenue for 2024, the ability to achieve this growth amidst a decrease in membership will be critical to watch. The introduction of new metrics such as SG&A Expense Ratio provides additional transparency for investors and can be a tool for comparing operational efficiency against industry peers.

Oscar Health's improvement in the InsuranceCo Combined Ratio to 99.5% is notable, as it approaches the breakeven point. This ratio, which combines the Medical Loss Ratio and Administrative Expense Ratio, is a key indicator of an insurance company's profitability. A ratio below 100% means that the company is earning more in premiums than it is paying out in claims and expenses, which is a positive sign for potential long-term sustainability.

The Medical Loss Ratio improvement reflects well on Oscar's cost of care initiatives and pricing strategy, which are particularly important in the competitive health insurance industry. However, the industry standard for a healthy MLR typically ranges from 80% to 85%, so while Oscar's MLR is within this range, it will be important for the company to maintain or further improve this ratio to ensure competitiveness and profitability.

The decrease in membership for Oscar Health could be indicative of broader market trends or increased competition within the healthcare insurance sector. It's essential to analyze how Oscar's strategic partnerships, like the one with Cigna and their technology-driven approach are impacting customer acquisition and retention. The healthcare industry is increasingly competitive, with technology playing a key role in differentiation.

Investor confidence may be influenced by the company's forward-looking statements about 2024, including anticipated improvements in Total Revenue and Adjusted EBITDA. It will be important to assess whether these projections are attainable given the current trajectory and market conditions. Additionally, the introduction of new metrics suggests a strategic pivot that could be a response to investor feedback or a shift in internal management focus.

  • For the year ended December 31, 2023:
    • Direct and Assumed Policy Premiums of $6.6 billion, a 3% decrease YoY
    • Premiums earned of $5.7 billion, a 47% increase YoY
    • Medical Loss Ratio of 81.6%, a 370 bps improvement YoY
    • InsuranceCo Administrative Expense Ratio of 17.9%, a 270 bps improvement YoY
    • InsuranceCo Combined Ratio of 99.5%, a 640 bps improvement YoY
    • Adjusted Administrative Expense Ratio of 21.0%, a 350 bps improvement YoY
    • Net loss of $271 million, an improvement of $339 million YoY
    • Adjusted EBITDA loss of $45 million, an improvement of $417 million YoY

NEW YORK--(BUSINESS WIRE)-- Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

“Oscar reported strong 2023 results with most core metrics exceeding our expectations for the full year. We delivered on our commitment for Insurance Company Adjusted EBITDA profitability and have a clear line of sight into consolidated Adjusted EBITDA profitability in 2024,” said Mark Bertolini, CEO of Oscar. “We are pleased to serve more than 1.3 million members this year and remain focused on driving long-term sustainable margin expansion.”

Total Direct and Assumed Policy Premiums for 2023 were $6.6 billion, down 3% year-over-year (“YoY”), driven primarily by lower membership, partially offset by rate increases. Premiums earned of $5.7 billion for the year increased 47% YoY, driven primarily by the impact of deposit accounting for quota share reinsurance agreements, and lower risk transfer per member as a percent of premiums.

Oscar’s InsuranceCo Combined Ratio, which is the sum of its Medical Loss Ratio (“MLR”) and the InsuranceCo Administrative Expense Ratio, improved 640 bps YoY to 99.5% for 2023, driven by both an improved MLR and administrative cost efficiencies. Specifically, the MLR improved 370 bps YoY to 81.6%, due to targeted rate increases and a disciplined pricing strategy and total cost of care initiatives. The InsuranceCo Administrative Expense Ratio improved 270 bps YoY to 17.9%, due to lower distribution expenses and higher net premiums as a result of lower risk transfer per member as a percent of premiums.

The Adjusted Administrative Expense Ratio for 2023 improved 350 bps YoY to 21.0%, due to lower distribution expenses, higher net premiums as a result of lower risk transfer per member as a percent of premiums, and higher net investment income. The Adjusted EBITDA loss of $45 million improved by $417 million YoY, and decreased as a percentage of premiums before ceded reinsurance by 8 points as compared to the prior year. Net loss of $271 million improved by $339 million YoY and decreased as a percentage of premiums before ceded reinsurance by 7 points compared to the prior year.

The Company is introducing its outlook for 2024 including two new metrics, Total Revenue and SG&A Expense Ratio. The Company anticipates Total Revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, a SG&A Expense Ratio of 20.5% to 21.0%, and Total Company Adjusted EBITDA of $125 million to $175 million. For more information on these metrics, see the “2024 Outlook and Supplemental Information” on page 3 in this release.

Financial Results Summary

 

 

 

 

 

 

 

 

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Premiums before ceded reinsurance

$

1,391,193

 

 

$

1,332,931

 

 

$

5,696,978

 

 

$

5,334,520

 

Reinsurance premiums ceded

 

(798

)

 

 

(365,474

)

 

 

(10,909

)

 

 

(1,463,403

)

Premiums earned

$

1,390,395

 

 

$

967,457

 

 

$

5,686,069

 

 

$

3,871,117

 

Total revenue

$

1,431,658

 

 

$

995,127

 

 

$

5,862,869

 

 

$

3,963,638

 

Total operating expenses

$

1,577,135

 

 

$

1,217,606

 

 

$

6,098,484

 

 

$

4,553,505

 

Net loss

$

(149,838

)

 

$

(226,560

)

 

$

(270,594

)

 

$

(609,552

)

Key Metrics and Non-GAAP Financial Metrics

 

 

 

 

 

 

 

 

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands, except percentages)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Direct and Assumed Policy Premiums

$

1,676,673

 

 

$

1,784,012

 

 

$

6,647,658

 

 

$

6,842,439

 

Medical Loss Ratio

 

86.4

%

 

 

91.6

%

 

 

81.6

%

 

 

85.3

%

InsuranceCo Administrative Expense Ratio

 

18.8

%

 

 

22.3

%

 

 

17.9

%

 

 

20.6

%

InsuranceCo Combined Ratio

 

105.2

%

 

 

113.9

%

 

 

99.5

%

 

 

105.8

%

Adjusted Administrative Expense Ratio

 

22.7

%

 

 

26.0

%

 

 

21.0

%

 

 

24.6

%

Adjusted EBITDA (1)

$

(111,593

)

 

$

(189,656

)

 

$

(45,238

)

 

$

(462,255

)

(1)

 

Adjusted EBITDA is a non-GAAP measure. See “Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA” in this release for a reconciliation to net loss, the most directly comparable GAAP measure, and for information regarding Oscar’s use of Adjusted EBITDA.

Membership by Offering

 

As of December 31,

 

 

 

2023

 

 

 

2022

 

Individual and Small Group

 

967,002

 

 

 

1,084,404

 

Medicare Advantage

 

 

1,781

 

 

 

4,452

 

Cigna + Oscar (1)

 

 

67,500

 

 

 

62,627

 

Total Members

 

 

1,036,283

 

 

 

1,151,483

 

(1)

 

Represents total membership for Oscar’s co-branded partnership with Cigna.

2024 Outlook and Supplemental Information

We regularly review a number of metrics to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. Beginning in 2024, the Company intends to provide guidance on four metrics: Total Revenue, Medical Loss Ratio, SG&A Expense Ratio and Adjusted EBITDA. The following table presents the Company’s 2024 financial outlook, along with full year 2023 results for such measures, calculated in accordance with the Company’s intended reporting approach for future periods.

The information included in this table represents management's current estimates as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates. The historical financial information included in this table is unaudited and has no impact on the Company’s audited financial statements and results of operations to be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Oscar Health, Inc.

2024 Financial Guidance Summary

 

 

 

 

 

 

 

 

 

Full Year 2024 Outlook

(in thousands, except percentages)

Full Year 2023 Actual

 

Low

 

High

Total Revenue (1)

$

5,862,869

 

 

$

8,300,000

 

 

$

8,400,000

 

 

 

 

 

 

 

Medical Loss Ratio (2)

 

81.6

%

 

 

80.2

%

 

 

81.2

%

 

 

 

 

 

 

SG&A Expense Ratio (3)

 

24.3

%

 

 

20.5

%

 

 

21.0

%

 

 

 

 

 

 

Adjusted EBITDA (4) (5)

$

(45,238

)

 

$

125,000

 

 

$

175,000

 

(1)

 

Total Revenue includes Net Premiums, Service revenue generated from our +Oscar business, and Investment (and other) income. We believe Revenue is an important metric to assess the growth of our insurance business and our +Oscar business, as well as the earnings potential of our investment portfolio.

(2)

 

Medical loss ratio (MLR) is total medical expenses incurred less any member cost sharing as a percentage of premiums before ceded reinsurance. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for healthcare of our members to the premiums before ceded reinsurance.

(3)

 

The Selling, General, and Administrative (SG&A) Expense ratio is calculated as selling, general and administrative expenses as a percentage of Total Revenue. We believe the SG&A Expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.

(4)

 

Adjusted EBITDA, a non-GAAP measure, is defined as Net Income (Loss) for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), depreciation and amortization, as further adjusted for stock-based compensation, and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry.

(5)

 

Oscar has not provided a quantitative reconciliation of forecasted Adjusted EBITDA to forecasted GAAP net loss within this press release because Oscar is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, stock-based compensation expense. These items, which could materially affect the computation of forecasted GAAP net loss, are inherently uncertain and depend on various factors, some of which are outside of Oscar’s control. As such, any associated estimate and its impact on GAAP net loss could vary materially.

Quarterly Conference Call Details

Oscar will host a conference call to discuss the financial results today, February 7, 2024, at 5:00 p.m. (ET). A live audio webcast will be available via the Investor Relations page of Oscar’s website at ir.hioscar.com. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP Financial Information

This release presents Adjusted EBITDA and InsuranceCo Adjusted EBITDA, non-GAAP financial metrics, which are provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. For more information regarding Adjusted EBITDA, please see “Key Operating and Non-GAAP Financial Metrics” below.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including Total Revenue, Medical Loss Ratio, SG&A Expense Ratio and Adjusted EBITDA and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, and our management’s plans and objectives for future operations, expectations and business strategy. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.

Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively; our ability to retain and expand our member base; heightened competition in the markets in which we participate; our ability to accurately estimate our incurred medical expenses or effectively manage our medical costs or related administrative costs; our ability to achieve or maintain profitability in the future; changes in federal or state laws or regulations, including changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”) and any regulations enacted thereunder; our ability to comply with ongoing regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the health insurance markets in the United States, including passage and implementation of a law to create a single-payer or government-run health insurance program; our, or any of our vendor’s, ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs, such as Medicare; our ability to arrange for the delivery of quality care and maintain good relations with the physicians, hospitals, and other providers within and outside our provider networks; unanticipated results of, or changes to, risk adjustment programs; our ability to utilize quota share reinsurance to reduce our capital and surplus requirements and protect against downside risk on medical claims; unfavorable or otherwise costly outcomes of lawsuits and claims that arise from the extensive laws and regulations to which we are subject; our ability to attract and retain qualified personnel; incurrence of data security breaches of our and our partners’ information and technology systems; our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or “controlled company” status; and the other factors set forth under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC, including our Annual Report on Form 10-K for the annual period ended December 31, 2023, to be filed with the SEC.

You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

About Oscar Health

Oscar Health, Inc. (“Oscar”) is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the healthcare system's status quo since our founding in 2012. The company’s member-first philosophy and innovative approach to care has earned us the trust of one million members, as of December 31, 2023. We offer Individual & Family and Small Group plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor healthcare to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members’ experience by building trust through deep engagement, personalized guidance, and rapid iteration.

Oscar Health, Inc.

Consolidated Statements of Operations

 

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands, except share and per share amounts)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

(unaudited)

 

(unaudited)

 

(unaudited)

 

 

Revenue

 

 

 

 

 

 

 

Premiums before ceded reinsurance

$

1,391,193

 

 

$

1,332,931

 

 

$

5,696,978

 

 

$

5,334,520

 

Reinsurance premiums ceded

 

(798

)

 

$

(365,474

)

 

 

(10,909

)

 

 

(1,463,403

)

Premiums earned

 

1,390,395

 

 

 

967,457

 

 

 

5,686,069

 

 

 

3,871,117

 

Administrative services revenue

 

3,830

 

 

 

2,681

 

 

 

15,442

 

 

 

61,047

 

Investment income and other revenue

 

37,433

 

 

 

24,989

 

 

 

161,358

 

 

 

31,474

 

Total revenue

 

1,431,658

 

 

 

995,127

 

 

 

5,862,869

 

 

 

3,963,638

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

Claims incurred, net

 

1,205,239

 

 

 

884,904

 

 

 

4,642,024

 

 

 

3,280,798

 

Other insurance costs

 

206,379

 

 

 

195,859

 

 

 

824,457

 

 

 

706,439

 

General and administrative expenses

 

85,610

 

 

 

75,808

 

 

 

339,716

 

 

 

309,783

 

Federal and state assessments

 

74,311

 

 

 

71,788

 

 

 

290,725

 

 

 

281,518

 

Premium deficiency reserve (release)

 

5,596

 

 

 

(10,753

)

 

 

1,562

 

 

 

(25,033

)

Total operating expenses

 

1,577,135

 

 

 

1,217,606

 

 

 

6,098,484

 

 

 

4,553,505

 

Loss from operations

 

(145,477

)

 

 

(222,479

)

 

 

(235,615

)

 

 

(589,867

)

Interest expense

 

6,217

 

 

 

6,135

 

 

 

24,603

 

 

 

22,623

 

Other expenses (income)

 

(1,050

)

 

 

(1,339

)

 

 

7,082

 

 

 

(2,415

)

Loss before income taxes

 

(150,644

)

 

 

(227,275

)

 

 

(267,300

)

 

 

(610,075

)

Income tax expense (benefit)

 

(806

)

 

 

(715

)

 

 

3,294

 

 

 

(523

)

Net loss

 

(149,838

)

 

 

(226,560

)

 

 

(270,594

)

 

 

(609,552

)

Less: Net income (loss) attributable to noncontrolling interests

$

192

 

 

$

(514

)

 

$

134

 

 

$

(3,277

)

Net loss attributable to Oscar Health, Inc.

$

(150,030

)

 

$

(226,046

)

 

$

(270,728

)

 

$

(606,275

)

 

 

 

 

 

 

 

 

Earnings (Loss) per Share

 

 

 

 

 

 

 

Net loss per share attributable to Oscar Health, Inc., basic and diluted

$

(0.66

)

 

$

(1.05

)

 

$

(1.22

)

 

$

(2.85

)

Weighted average common shares outstanding, basic and diluted

 

227,082,062

 

 

 

215,194,230

 

 

 

221,655,493

 

 

 

212,474,615

 

Oscar Health, Inc.

Consolidated Balance Sheets

 

(in thousands, except share and per share amounts)

December 31, 2023

 

December 31, 2022

 

(unaudited)

 

 

Assets:

 

 

 

Current Assets:

 

 

 

Cash and cash equivalents

1,870,315

 

 

1,558,595

 

Short-term investments

 

689,833

 

 

 

1,397,287

 

Premiums and accounts receivable (net of allowance for credit losses of $31,600 and $2,988)

 

201,269

 

 

 

216,475

 

Risk adjustment transfer receivable

 

51,925

 

 

 

49,861

 

Reinsurance recoverable

 

241,194

 

 

 

892,887

 

Other current assets

 

6,564

 

 

 

6,450

 

Total current assets

 

3,061,100

 

 

 

4,121,555

 

Property, equipment, and capitalized software, net

 

61,930

 

 

 

59,888

 

Long-term investments

 

365,309

 

 

 

222,919

 

Restricted deposits

 

29,870

 

 

 

27,483

 

Other assets

 

83,271

 

 

 

94,756

 

Total Assets

 

3,601,480

 

 

 

4,526,601

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

Current Liabilities:

 

 

 

Benefits payable

 

965,986

 

 

 

937,727

 

Risk adjustment transfer payable

 

1,056,941

 

 

 

1,517,493

 

Premium deficiency reserve

 

5,776

 

 

 

4,214

 

Unearned premiums

 

65,918

 

 

 

78,998

 

Accounts payable and other liabilities

 

273,367

 

 

 

297,841

 

Reinsurance payable

 

61,024

 

 

 

427,649

 

Total current liabilities

 

2,429,012

 

 

 

3,263,922

 

Long-term debt

 

298,777

 

 

 

297,999

 

Other liabilities

 

67,574

 

 

 

72,280

 

Total liabilities

 

2,795,363

 

 

 

3,634,201

 

Commitments and contingencies

 

 

 

Stockholders' Equity

 

 

 

Class A common stock, $0.00001 par value; 825,000,000 shares authorized, 193,874,843 and 181,176,239 shares outstanding as of December 31, 2023 and 2022, respectively

 

2

 

 

 

2

 

Class B common stock, $0.00001 par value; 82,500,000 shares authorized, 35,514,201 and 35,115,807 shares outstanding as of December 31, 2023 and 2022, respectively

 

 

 

 

 

Treasury stock (314,600 shares as of December 31, 2023 and 2022)

 

(2,923

)

 

 

(2,923

)

Additional paid-in capital

 

3,682,294

 

 

 

3,509,007

 

Accumulated deficit

 

(2,876,715

)

 

 

(2,605,987

)

Accumulated other comprehensive income (loss)

 

1,309

 

 

 

(9,715

)

Total Oscar Health, Inc. stockholders’ equity

 

803,967

 

 

 

890,384

 

Noncontrolling interests

 

2,150

 

 

 

2,016

 

Total stockholders’ equity

 

806,117

 

 

 

892,400

 

Total Liabilities and Stockholders' Equity

 

3,601,480

 

 

 

4,526,601

 

Oscar Health, Inc.

Consolidated Statements of Cash Flows

 

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

(unaudited)

 

 

Cash flows from operating activities:

 

 

 

Net loss

 

(270,594

)

 

$

(609,552

)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

 

Deferred taxes

58

 

 

 

(165

)

Net realized loss (gain) on sale of financial instruments

 

70

 

 

 

1,274

 

Depreciation and amortization expense

 

30,694

 

 

 

15,283

 

Amortization of debt issuance costs

 

778

 

 

 

713

 

Stock-based compensation expense

 

159,683

 

 

 

112,329

 

Net amortization (accretion) of investments

 

(29,374

)

 

 

2,480

 

Provision for credit losses

 

28,612

 

 

 

2,988

 

Changes in assets and liabilities:

 

 

 

(Increase) / decrease in:

 

 

 

Premiums and accounts receivable

 

(13,405

)

 

 

(81,049

)

Risk adjustment transfer receivable

 

(2,063

)

 

 

(9,202

)

Reinsurance recoverable

 

651,693

 

 

 

(460,897

)

Other assets

 

11,307

 

 

 

(243

)

Increase / (decrease) in:

 

 

 

Benefits payable

 

28,258

 

 

 

424,146

 

Unearned premiums

 

(13,080

)

 

 

3,953

 

Premium deficiency reserve

 

1,562

 

 

 

(25,033

)

Accounts payable and other liabilities

 

(29,180

)

 

 

57,811

 

Reinsurance payable

 

(366,626

)

 

 

222,418

 

Risk adjustment transfer payable

 

(460,552

)

 

 

723,095

 

Net cash (used in) provided by operating activities

 

(272,159

)

 

 

380,349

 

Cash flows from investing activities:

 

 

 

Purchase of investments

 

(836,982

)

 

 

(1,192,706

)

Sale of investments

 

31,857

 

 

 

360,616

 

Maturity of investments

 

1,410,166

 

 

 

633,467

 

Purchase of property, equipment and capitalized software

 

(25,577

)

 

 

(29,012

)

Change in restricted deposits

 

(2,277

)

 

 

1,116

 

Net cash (used in) provided by investing activities

 

577,187

 

 

 

(226,519

)

Cash flows from financing activities:

 

 

 

Proceeds from long-term debt

 

 

 

 

305,000

 

Payments of debt issuance costs

 

 

 

 

(7,035

)

Proceeds from joint venture contribution

 

2,490

 

 

 

1,846

 

Proceeds from exercise of stock options

 

3,956

 

 

 

1,299

 

Net cash provided by financing activities

 

6,446

 

 

 

301,110

 

Increase in cash, cash equivalents and restricted cash equivalents

 

311,474

 

 

 

454,940

 

Cash, cash equivalents, restricted cash and cash equivalents—beginning of period

 

1,580,497

 

 

 

1,125,557

 

Cash, cash equivalents, restricted cash and cash equivalents—end of period

$

1,891,971

 

 

$

1,580,497

 

 

 

 

 

Cash and cash equivalents

 

1,870,315

 

 

 

1,558,595

 

Restricted cash and cash equivalents included in restricted deposits

 

21,656

 

 

 

21,902

 

Total cash, cash equivalents and restricted cash and cash equivalents

$

1,891,971

 

 

$

1,580,497

 

 

Year Ended December 31,

(in thousands)

 

2023

 

 

2022

Supplemental Disclosures:

 

 

 

Interest payments

$

23,156

 

 

$

10,079

 

Income tax payments

$

2,414

 

 

$

1,893

 

Key Operating and Non-GAAP Financial Metrics

We regularly review a number of metrics, including the following key operating and non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.

Members

Members are defined as any individual covered by a health plan that we offer directly or through a co-branded arrangement. We view the number of members enrolled in our health plans as an important metric to help evaluate and estimate revenue and market share. Additionally, the more members we enroll, the more data we have, which allows us to improve the functionality of our platform.

Direct and Assumed Policy Premiums

Direct policy premiums are defined as the premiums collected from our members or from the federal government during the period indicated, before risk adjustment and reinsurance. These premiums include APTC, or premium subsidies, which are available to individuals and families with certain annual incomes.

Assumed policy premiums are premiums we receive primarily as part of our reinsurance arrangement under our Cigna+Oscar Small Group plan offering, and are presented here net of risk adjustment.

We believe Direct and Assumed Policy Premiums is an important metric to assess the growth of our individual and small group plan offerings going forward. Management also views Direct and Assumed Policy Premiums as a key operating metric because Direct and Assumed Policy Premiums are a key input in the calculation of our MLR, InsuranceCo Administrative Expense Ratio, InsuranceCo Combined Ratio and Adjusted Administrative Expense Ratio.

Medical Loss Ratio

Medical Loss Ratio is calculated as set forth in the table below. Direct claims incurred before ceded reinsurance are medical claims, the total medical expenses incurred in order for members to utilize healthcare services less any member cost sharing. These services include inpatient, outpatient, pharmacy, and physician costs. Direct claims incurred before ceded reinsurance also include risk sharing arrangements with certain of our providers. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for healthcare of our members to net premiums before ceded quota share reinsurance. MLRs in our existing products are subject to various federal and state minimum requirements.

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands, except percentages)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Direct claims incurred before ceded reinsurance (1)

$

1,158,278

 

 

$

1,172,279

 

 

$

4,459,702

 

 

$

4,428,000

 

Assumed reinsurance claims

 

57,864

 

 

 

47,683

 

 

 

227,058

 

 

 

143,147

 

Excess of loss ceded claims (2)

 

2,921

 

 

 

(4,316

)

 

 

(3,117

)

 

 

(18,632

)

State reinsurance (3)

 

(17,102

)

 

 

(1,901

)

 

 

(43,676

)

 

 

(30,544

)

Net claims before ceded quota share reinsurance (A)

$

1,201,961

 

 

$

1,213,745

 

 

$

4,639,967

 

 

$

4,521,971

 

 

 

 

 

 

 

 

 

Premiums before ceded reinsurance

$

1,391,193

 

 

$

1,332,931

 

 

$

5,696,978

 

 

$

5,334,520

 

Excess of loss reinsurance premiums (4)

 

(717

)

 

 

(8,115

)

 

 

(8,698

)

 

 

(31,502

)

Net premiums before ceded quota share reinsurance (B)

$

1,390,476

 

 

$

1,324,816

 

 

$

5,688,280

 

 

$

5,303,018

 

Medical Loss Ratio (A divided by B)

 

86.4

%

 

 

91.6

%

 

 

81.6

%

 

 

85.3

%

(1)

 

See the Appendix to this release for a reconciliation of direct claims incurred to claims incurred, net appearing on the face of our statement of operations.

(2)

 

Represents claims ceded to reinsurers pursuant to an excess of loss treaty, for which such reinsurers are financially liable. We use excess of loss reinsurance to limit the losses on individual claims of our members.

(3)

 

Represents payments made by certain state-run reinsurance programs established subject to CMS approval under Section 1332 of the ACA.

(4)

 

Represents excess of loss reinsurance premiums paid.

InsuranceCo Administrative Expense Ratio

InsuranceCo Administrative Expense Ratio is calculated as set forth in the table below. The ratio reflects the costs associated with running our insurance companies. We believe InsuranceCo Administrative Expense Ratio is useful to evaluate our ability to manage our expenses as a percentage of net premiums before quota share reinsurance. Expenses necessary to run the insurance companies are included in Other insurance costs and Federal and state assessments. These expenses include variable expenses paid to distribution partners and vendors, premium taxes and healthcare exchange fees, employee-related compensation, benefits, marketing costs, and other administrative expenses.

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands, except percentages)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Other insurance costs

$

206,379

 

 

$

195,859

 

 

$

824,457

 

 

$

706,439

 

Impact of quota share reinsurance (1)

 

(7,023

)

 

 

40,745

 

 

 

(30,454

)

 

 

154,741

 

Stock-based compensation expense

 

(11,458

)

 

 

(13,043

)

 

 

(66,060

)

 

 

(51,495

)

Federal and state assessment of health insurance subsidiaries

 

73,915

 

 

 

71,471

 

 

 

289,647

 

 

 

281,049

 

Health insurance subsidiary adjusted administrative expenses (A)

$

261,813

 

 

$

295,032

 

 

$

1,017,590

 

 

$

1,090,734

 

 

 

 

 

 

 

 

 

Premiums before ceded reinsurance

$

1,391,193

 

 

$

1,332,931

 

 

$

5,696,978

 

 

$

5,334,520

 

Excess of loss reinsurance premiums

 

(717

)

 

 

(8,115

)

 

 

(8,698

)

 

 

(31,502

)

Net premiums before ceded quota share reinsurance (B)

$

1,390,476

 

 

$

1,324,816

 

 

$

5,688,280

 

 

$

5,303,018

 

InsuranceCo Administrative Expense Ratio (A divided by B)

 

18.8

%

 

 

22.3

%

 

 

17.9

%

 

 

20.6

%

(1)

 

Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(6,996) and $(1,788) for the three months ended December 31, 2023 and 2022, respectively and $(29,451) and $(7,205) for the year ended December 31, 2023 and 2022, respectively.

InsuranceCo Combined Ratio

InsuranceCo Combined Ratio is defined as the sum of MLR and InsuranceCo Administrative Expense Ratio. We believe this ratio best represents the core performance of the insurance business, prior to the impact of quota share and net investment income.

 

Three Months Ended December 31,

 

Year Ended December 31,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Medical Loss Ratio

 

86.4

%

 

 

91.6

%

 

 

81.6

%

 

 

85.3

%

InsuranceCo Administrative Expense Ratio

 

18.8

%

 

 

22.3

%

 

 

17.9

%

 

 

20.6

%

InsuranceCo Combined Ratio

 

105.2

%

 

 

113.9

%

 

 

99.5

%

 

 

105.8

%

Adjusted Administrative Expense Ratio

The Adjusted Administrative Expense Ratio is an operating ratio that reflects the Company’s total administrative expenses (“Total Administrative Expenses”), net of non-cash and non-recurring items (as adjusted, “Adjusted Administrative Expenses”), as a percentage of total revenue, excluding the impact of quota share reinsurance premiums less excess of loss reinsurance premiums ceded (“Adjusted Total Revenue”). Total Administrative Expenses are calculated as Total operating expenses, excluding non-administrative insurance-based expenses and the impact of quota share reinsurance. Adjusted Administrative Expenses are Total Administrative Expenses, net of non-cash and non-recurring expense items. We believe Adjusted Administrative Expense Ratio is useful to evaluate our ability to manage our overall administrative expense base. This ratio also provides further clarity into our overall path to profitability.

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands, except percentages)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Total Operating Expenses

$

1,577,135

 

 

$

1,217,606

 

 

$

6,098,484

 

 

$

4,553,505

 

Claims incurred, net

 

(1,205,239

)

 

 

(884,904

)

 

 

(4,642,024

)

 

 

(3,280,798

)

Premium deficiency reserve (release)

 

(5,596

)

 

 

10,753

 

 

 

(1,562

)

 

 

25,033

 

Impact of quota share reinsurance (1)

 

(7,023

)

 

 

40,745

 

 

 

(30,454

)

 

 

154,741

 

Total Administrative Expenses

$

359,277

 

 

$

384,200

 

 

$

1,424,444

 

 

$

1,452,481

 

Stock-based compensation expense

 

(26,142

)

 

 

(29,088

)

 

 

(159,683

)

 

 

(112,329

)

Depreciation and amortization

 

(7,742

)

 

 

(3,735

)

 

 

(30,694

)

 

 

(15,283

)

Adjusted Administrative Expenses (A)

$

325,393

 

 

$

351,377

 

 

$

1,234,067

 

 

$

1,324,869

 

Total Revenue

$

1,431,658

 

 

$

995,127

 

 

$

5,862,869

 

 

$

3,963,638

 

Reinsurance premiums ceded

 

798

 

 

 

365,474

 

 

 

10,909

 

 

 

1,463,403

 

Excess of loss reinsurance premiums

 

(717

)

 

 

(8,115

)

 

 

(8,698

)

 

 

(31,502

)

Adjusted Total Revenue (B)

$

1,431,739

 

 

$

1,352,486

 

 

$

5,865,080

 

 

$

5,395,539

 

Adjusted Administrative Expense Ratio (A divided by B)

 

22.7

%

 

 

26.0

%

 

 

21.0

%

 

 

24.6

%

(1)

 

Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(6,996) and $(1,788) for the three months ended December 31, 2023 and 2022, respectively, and $(29,451) and $(7,205) for the year ended December 31, 2023 and 2022, respectively.

SG&A Expense Ratio

The Company is transitioning to the SG&A Expense Ratio as the operating ratio that reflects the Company’s administrative expenses, as a percentage of total revenue, without exclusions for the impact of quota share, premium deficiency reserve (release), or stock compensation. Total SG&A Expenses are calculated as Total operating expenses, less Claims incurred, net, and Depreciation and amortization. The SG&A Expense ratio is calculated as selling, general and administrative expenses as a percentage of Total Revenue. We believe the SG&A Expense Ratio is useful to evaluate our ability to manage our administrative expenses.

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands, except percentages)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Adjusted Administrative Expenses

$

325,393

 

 

$

351,377

 

 

$

1,234,067

 

 

$

1,324,869

 

Premium deficiency reserve (release)

 

5,596

 

 

 

(10,753

)

 

 

1,562

 

 

 

(25,033

)

Impact of quota share reinsurance (1)

 

7,023

 

 

 

(40,745

)

 

 

30,454

 

 

 

(154,741

)

Stock-based compensation expense

 

26,142

 

 

 

29,088

 

 

 

159,683

 

 

 

112,329

 

Total SG&A Expenses (A)

$

364,154

 

 

$

328,967

 

 

$

1,425,766

 

 

$

1,257,424

 

Total Revenue (B)

$

1,431,658

 

 

$

995,127

 

 

$

5,862,869

 

 

$

3,963,638

 

SG&A Expense Ratio (A divided by B)

 

25.4

%

 

 

33.1

%

 

 

24.3

%

 

 

31.7

%

Adjusted EBITDA

Adjusted EBITDA is defined as Net loss for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), and depreciation and amortization as further adjusted for stock-based compensation, and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.

Management uses Adjusted EBITDA:

  • as a measurement of operating performance because it assists us in comparing the operating performance of our business on a consistent basis, as it removes the impact of items not directly resulting from our core operations;
  • for planning purposes, including the preparation of our internal annual operating budget and financial projections;
  • to evaluate the performance and effectiveness of our operational strategies; and
  • to evaluate our capacity to expand our business.

By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net loss, we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for Net loss or other financial statement data presented in our Consolidated Financial Statements as indicators of financial performance.

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Net loss

$

(149,838

)

 

$

(226,560

)

 

$

(270,594

)

 

$

(609,552

)

Interest expense

 

6,217

 

 

 

6,135

 

 

 

24,603

 

 

 

22,623

 

Other expenses (income)

 

(1,050

)

 

 

(1,339

)

 

 

7,082

 

 

 

(2,415

)

Income tax expense (benefit)

 

(806

)

 

 

(715

)

 

 

3,294

 

 

 

(523

)

Depreciation and amortization (“D&A”)

 

7,742

 

 

 

3,735

 

 

 

30,694

 

 

 

15,283

 

Stock-based compensation (“SBC”) (1)

 

26,142

 

 

 

29,088

 

 

 

159,683

 

 

 

112,329

 

Adjusted EBITDA

$

(111,593

)

 

$

(189,656

)

 

$

(45,238

)

 

$

(462,255

)

 

 

 

 

 

 

 

 

General and administrative expenses (excluding SBC and D&A)

$

70,505

 

 

$

59,341

 

 

$

244,085

 

 

$

246,735

 

Administrative services revenue

$

(3,830

)

 

$

(2,682

)

 

$

(15,442

)

 

 

(61,047

)

Investment income and other revenue (Non-InsuranceCo)

$

(4,735

)

 

$

(2,027

)

 

$

(14,672

)

 

$

(5,711

)

InsuranceCo Adjusted EBITDA (2)

$

(49,653

)

 

$

(135,024

)

 

$

168,733

 

 

$

(282,278

)

(1)

 

Represents non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number, and the valuation of awards. Year ended December 31, 2023 includes a non-recurring charge of $46.3 million related to accelerated stock-based compensation expense recognized as a result of the cancellation of the Founders Awards previously granted to Mario Schlosser and Joshua Kushner.

(2)

 

We believe that InsuranceCo Adjusted EBITDA provides investors with additional insight into the earnings and capital generation potential of the Company’s insurance subsidiaries.

Appendix

Reinsurance Impact

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Quota share ceded premiums

$

222

 

 

$

(372,168

)

 

$

7,329

 

 

$

(1,489,525

)

Quota share ceded claims

 

(3,277

)

 

 

328,841

 

 

 

(2,056

)

 

 

1,241,173

 

Ceding commission, net of deposit accounting impact (1)

 

(7,023

)

 

 

40,745

 

 

 

(30,454

)

 

 

154,741

 

Experience refund

 

(302

)

 

 

14,809

 

 

 

(9,540

)

 

 

57,625

 

Net quota share impact

$

(10,380

)

 

$

12,227

 

 

$

(34,721

)

 

$

(35,986

)

(1)

 

Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(6,996) and $(1,788) for the three months ended December 31, 2023 and 2022, respectively, and $(29,451) and $(7,205) for the year ended December 31, 2023 and 2022, respectively.

The composition of total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total premiums earned in the consolidated statement of operations, is as follows:

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Reinsurance premiums ceded, gross

 

(1,458

)

 

 

(380,592

)

 

 

56

 

 

 

(1,524,157

)

Experience refunds

 

660

 

 

 

15,118

 

 

 

(10,965

)

 

 

60,754

 

Reinsurance premiums ceded

 

(798

)

 

 

(365,474

)

 

 

(10,909

)

 

 

(1,463,403

)

Reinsurance premiums assumed

 

54,620

 

 

 

41,815

 

 

 

228,786

 

 

 

138,109

 

Total reinsurance premiums (ceded) and assumed, net

 

53,822

 

 

 

(323,659

)

 

 

217,877

 

 

 

(1,325,294

)

The Company records claims expense net of reinsurance recoveries. The following table reconciles the total claims expense to the net claims expense as presented in the consolidated statement of operations:

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Direct claims incurred

 

1,158,278

 

 

 

1,172,279

 

 

 

4,459,702

 

 

 

4,428,000

 

Ceded reinsurance claims

 

(10,903

)

 

 

(335,058

)

 

 

(44,736

)

 

 

(1,290,349

)

Assumed reinsurance claims

 

57,864

 

 

 

47,683

 

 

 

227,058

 

 

 

143,147

 

Claims incurred, net

 

1,205,239

 

 

 

884,904

 

 

 

4,642,024

 

 

 

3,280,798

 

The Company records selling, general and administrative expenses net of ceding commissions. The following table reconciles total other insurance costs to the amount presented in the consolidated statement of operations:

 

Three Months Ended December 31,

 

Year Ended December 31,

(in thousands)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Other insurance costs, gross

 

206,353

 

 

 

238,392

 

 

 

823,455

 

 

 

868,385

 

Reinsurance ceding commissions

 

26

 

 

(42,533

)

 

 

1,002

 

 

(161,946

)

Other insurance costs

 

206,379

 

 

 

195,859

 

 

 

824,457

 

 

 

706,439

 

The Company classifies reinsurance recoverable within current assets on its consolidated balance sheets. The composition of the reinsurance recoverable balance is as follows:

 

 

As of December 31,

(in thousands)

 

 

2023

 

 

 

2022

 

Ceded reinsurance claim recoverables

 

$

225,705

 

 

$

776,266

 

Reinsurance ceding commissions

 

 

6,185

 

 

 

42,805

 

Experience refunds on reinsurance agreements

 

 

9,304

 

 

 

73,816

 

Reinsurance recoverable

 

$

241,194

 

 

$

892,887

 

 

Investor Contact:

Chris Potochar

VP of Investor Relations

ir@hioscar.com

Media Contact:

Kristen Prestano

VP of Communications

press@hioscar.com

Source: Oscar Health, Inc.

FAQ

What were Oscar Health's Direct and Assumed Policy Premiums for 2023?

Oscar Health's Direct and Assumed Policy Premiums for 2023 were $6.6 billion, down 3% YoY.

What was the Medical Loss Ratio for 2023?

The Medical Loss Ratio for 2023 improved by 370 bps YoY to 81.6%.

What is the company's outlook for Total Revenue in 2024?

The company anticipates Total Revenue of $8.3 billion to $8.4 billion for 2024.

What is the Adjusted EBITDA loss for 2023?

The Adjusted EBITDA loss for 2023 was $45 million.

How much did the Net loss improve by in 2023?

The Net loss improved by $339 million YoY in 2023.

Oscar Health, Inc.

NYSE:OSCR

OSCR Rankings

OSCR Latest News

OSCR Stock Data

4.11B
195.51M
3.02%
85.57%
5.02%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States of America
NEW YORK